TUSTIN, Calif., Nov. 17 /PRNewswire-FirstCall/ -- AMDL, Inc. , a leading vertically integrated bio-pharmaceutical company with operations in China and the U.S., today reported results and the filing of its Quarterly Report on Form 10-Q with the Securities and Exchange Commission ("SEC") for the third quarter ended September 30, 2008. The Company reported gross revenues of $12.4 million -- an increase of 113% compared with $5.8 million in sales reported for the same period in 2007.

Gross profits for the third quarter ended September 30, 2008 increased to $4.9 million compared to $3.6 million for the same period in 2007. The Company's consolidated net income for the third quarter ended September 30, 2008 was $1.569 million or $0.10 per share (unaudited) compared to consolidated net income of $383,108 or $0.03 per share for the same period in 2007. Comprehensive gains after foreign currency translation were $1.634 million for the third quarter ended September 30, 2008 compared to a gain of $631,026 for the same period in 2007.

"We are pleased to report another quarter of strong revenue and net income growth. The success of our increased sales and distribution efforts and diversified product portfolio focusing has enabled us to achieve a 113% increase in revenues for the quarter," commented Mr. Douglas MacLellan, CEO and Chairman, AMDL, Inc. "We are extremely pleased with the Company's third quarter results which are right on target with AMDL's stated guidance forecasts. AMDL's extraordinary growth is clear evidence that we are successfully executing on a business strategy that will deliver profitable results for our employees, customers and shareholders, and moving ahead into the fourth quarter we reiterate we expect AMDL's 2008 full-year revenue growth to exceed 100%."

For FY2008 AMDL has targeted net sales ranging between $32 to $36 million -- more than a 100% increase over the same period in 2007 where the Company achieved gross revenues of $15 million.

The Company estimates net income before foreign currency translation to be between $1.8 and $ 2.2 million for FY2008.

AMDL will conduct a conference call with investors to discuss its third quarter 2008 financial results and current financial prospects on Tuesday, November 18, 2008 at 6:30 a.m. Pacific Time (9:30 a.m. Eastern Time). Listeners may access the call by dialing 1-877-360-1705 or 1-706-902-3245 for international callers, access code: 12310; conference ID 74287692. To listen to the conference call after the live presentation, or to view the financial or other statistical information required by Securities and Exchange Commission (SEC) Regulation G, please visit the Investors section of the AMDL website at http://www.amdl.com. The conference call will be recorded and available for listening until 5:00 p.m. Pacific Time, Wednesday, November 19, 2008.

About AMDL:

Headquartered in Tustin, CA with operations in Shenzhen, Jiangxi, and Jilin, China, AMDL, Inc., along with its subsidiary Jade Pharmaceutical Inc. (JPI), is a vertically integrated bio-pharmaceutical company devoted to the research, development, manufacturing, and marketing of diagnostic, pharmaceutical, nutritional supplement, and cosmetic products. The company employs approximately 500 people in the U.S. and China.

Forward-Looking Statements:

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to AMDL, Inc., except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties related to the Company's access to additional capital, competition and dependence on key management.

CONTACT: Kristine Szarkowitz, Director-Investor Relations of AMDL, Inc.,
+1-206-310-5323, kszarkowitz@amdl.com

Web site: http://www.amdl.com/